Theratechnologies Completes Acquisition by Future Pak for $3.01 Per Share Plus Contingent Value Rights

Theratechnologies, a commercial-stage biopharmaceutical company, has completed its acquisition by Future Pak. The company's shares have been acquired for $3.01 per share in cash, plus one contingent value right (CVR) per share for additional payments of up to $1.19 per CVR if certain milestones are achieved. The CVRs are recorded in a register kept by the CVR agent and are not evidenced by a certificate or any other instrument. The shares will be delisted from the Toronto Stock Exchange and Nasdaq Capital Market.